InterMune, Inc.
3280 Bayshore Boulevard
Brisbane
California
94005
United States
Tel: 415-466-2200
Fax: 415-466-2329
Website: http://www.intermune.com/
About InterMune, Inc.
InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and hepatology. InterMune has a product portfolio addressing IPF and HCV infections. The pulmonology portfolio includes Actimmune®, which is being evaluated in the INSPIRE Trial, a Phase III study in patients with IPF, and pirfenidone, which is also being developed for the treatment of IPF. The hepatology portfolio includes the lead HCV protease inhibitor compound (ITMN B), a second-generation HCV protease inhibitor program, and a research program evaluating a new target in hepatology.For additional information about InterMune and its R&D pipeline, please visit: www.intermune.com
278 articles about InterMune, Inc.
-
Ex-InterMune Executive, Friend Found Liable For $1 Million Insider Trading Scheme
11/15/2016
-
With Ex-InterMune Exec at Its Helm, AveXis Scores $65 Million
9/9/2015
-
The Pink Slip Valentine: Companies Making Job Cuts: Sanofi, InterMune, Abbott, Syngenta AG, GlaxoSmithKline, Amgen
2/17/2015
-
Consolidation Begins as 170 InterMune, Inc. Workers to be Eliminated By Mid-February
1/12/2015
-
After $8.3 Billion Sale to Roche, InterMune, Inc. Chief Jumps to Venture Capital
1/9/2015
-
InterMune, Inc. Wins FDA Approval For Lung Drug At Center Of Roche Deal
10/17/2014
-
Roche Purchases Shares In Tender Offer For InterMune, Inc.
9/29/2014
-
InterMune, Inc. Reports Memorandum Of Understanding In Connection With Consolidated Delaware Action
9/23/2014
-
InterMune, Inc. Announces Anticipated Fundamental Change For 5.00% Convertible Senior Notes Due 2015
9/5/2014
-
Roche Pays $8.3 Billion For Bay Area's InterMune, Pledges To Keep Employees
8/26/2014
-
InterMune, Inc. CEO: Bittersweet Ending To A Biotech Comeback Story
8/26/2014
-
InterMune, Inc. Goes Up On The Block; GlaxoSmithKline, Roche, Sanofi (France) Line Up
8/18/2014
-
InterMune, Inc. Reports Second Quarter 2014 Financial Results And Business Highlights
8/7/2014
-
InterMune, Inc. To Release Second Quarter Financial Results On August 6
7/28/2014
-
InterMune, Inc. Grabs FDA Breakthough Therapy Designation For IPF Drug Pirfenidone
7/18/2014
-
InterMune, Inc. Announces Resubmission Of NDA For Pirfenidone For The Treatment Of Patients With IPF
5/27/2014
-
InterMune, Inc. Announces Additional Pirfenidone Data In Idiopathic Pulmonary Fibrosis
5/21/2014
-
InterMune, Inc. Rises After Fatal Lung Disease Drug Slows Damage In Phase 3 Study
5/20/2014
-
InterMune, Inc. Release: Phase 3 ASCEND Study Of Pirfenidone In Idiopathic Pulmonary Fibrosis Presented At American Thoracic Society And Published The New England Journal of Medicine
5/19/2014
-
InterMune, Inc. Announces Expanded Access Program For Pirfenidone To Treat Idiopathic Pulmonary Fibrosis (IPF) In The United States
5/16/2014